What's Next
Antibody discovery with LabGenius' James Field
June 06, 2024
Balderton Capital
Antibody discovery with LabGenius' James Field
What's Next
Chapters
0:00
Intro
5:25
How James’ PhD experience shaped his entrepreneurial journey
9:50
Why grants play a crucial role for deeptech startups
12:35
LabGenius’ fundraising experience
17:55
On growing the team
21:05
What does success look like for LabGenius in the next few years
21:59
Why now is the moment for synthetic biology
25:00
Changing scientific discovery through “silicone scientists”
33:47
LabGenius’ relationship with the pharmaceutical industry
36:16
Where software companies fit in
39:05
LabGenius' ultimate dream
What's Next
Antibody discovery with LabGenius' James Field
Jun 06, 2024
Balderton Capital
What do synthetic biology, machine learning and robotics have in common? James Field, CEO and founder of LabGenius, explains how his company is integrating bleeding-edge technologies from across these fields to discover the next-generation therapeutic antibodies. And change the way we approach drug discovery.
Find out more about Labgenius here and follow them on LinkedIn
What do synthetic biology, machine learning and robotics have in common? James Field, CEO and founder of LabGenius, explains how his company is integrating bleeding-edge technologies from across these fields to discover the next-generation therapeutic antibodies. And change the way we approach drug discovery.
Find out more about Labgenius here and follow them on LinkedIn